Mucosal delivery of RNA vaccines by Newcastle disease virus vectors
The rapid evolution of SARS-CoV-2 since its pandemic outbreak has underscored the need for improved SARS-CoV-2 vaccines that efficiently reduce not only hospitalizations and deaths, but also infections and transmission. This might be achieved by a new generation of intranasally administered SARS-CoV...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Current Research in Immunology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590255522000221 |
| _version_ | 1811295670484598784 |
|---|---|
| author | Adolfo García-Sastre |
| author_facet | Adolfo García-Sastre |
| author_sort | Adolfo García-Sastre |
| collection | DOAJ |
| description | The rapid evolution of SARS-CoV-2 since its pandemic outbreak has underscored the need for improved SARS-CoV-2 vaccines that efficiently reduce not only hospitalizations and deaths, but also infections and transmission. This might be achieved by a new generation of intranasally administered SARS-CoV-2 vaccines to stimulate protective mucosal immunity. Among all different approaches, preclinical and clinical information using Newcastle Disease Virus (NDV)-vectors expressing S of SARS-CoV2 as a COVID-19 vaccine show the potential of this vaccine platform as an affordable, highly immunogenic, safe strategy to intranasally vaccinate humans against SARS-CoV-2 and other infectious diseases. These vaccine vectors consist on the use of a harmless avian negative strand RNA virus to deliver intranasally a self-replicating RNA expressing the vaccine antigen in the cells of the respiratory mucosa. The vector also incorporates the antigen in the virus particle used for RNA delivery, thus combining the properties of nanoparticle-based and RNA-based vaccines. Other advantages of NDV-based vectors include the worldwide availability of manufacturing facilities for their production and their stability at non-freezing temperatures. While phase 3 clinical studies to evaluate efficacy are still pending, phase 1 and 2 clinical studies have demonstrated the safety and immunogenicity of NDV-S vaccines against SARS-CoV-2. |
| first_indexed | 2024-04-13T05:36:49Z |
| format | Article |
| id | doaj.art-95a786a90f264953935063ed6c0373f5 |
| institution | Directory Open Access Journal |
| issn | 2590-2555 |
| language | English |
| last_indexed | 2024-04-13T05:36:49Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Immunology |
| spelling | doaj.art-95a786a90f264953935063ed6c0373f52022-12-22T03:00:16ZengElsevierCurrent Research in Immunology2590-25552022-01-013234238Mucosal delivery of RNA vaccines by Newcastle disease virus vectorsAdolfo García-Sastre0Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.The rapid evolution of SARS-CoV-2 since its pandemic outbreak has underscored the need for improved SARS-CoV-2 vaccines that efficiently reduce not only hospitalizations and deaths, but also infections and transmission. This might be achieved by a new generation of intranasally administered SARS-CoV-2 vaccines to stimulate protective mucosal immunity. Among all different approaches, preclinical and clinical information using Newcastle Disease Virus (NDV)-vectors expressing S of SARS-CoV2 as a COVID-19 vaccine show the potential of this vaccine platform as an affordable, highly immunogenic, safe strategy to intranasally vaccinate humans against SARS-CoV-2 and other infectious diseases. These vaccine vectors consist on the use of a harmless avian negative strand RNA virus to deliver intranasally a self-replicating RNA expressing the vaccine antigen in the cells of the respiratory mucosa. The vector also incorporates the antigen in the virus particle used for RNA delivery, thus combining the properties of nanoparticle-based and RNA-based vaccines. Other advantages of NDV-based vectors include the worldwide availability of manufacturing facilities for their production and their stability at non-freezing temperatures. While phase 3 clinical studies to evaluate efficacy are still pending, phase 1 and 2 clinical studies have demonstrated the safety and immunogenicity of NDV-S vaccines against SARS-CoV-2.http://www.sciencedirect.com/science/article/pii/S2590255522000221 |
| spellingShingle | Adolfo García-Sastre Mucosal delivery of RNA vaccines by Newcastle disease virus vectors Current Research in Immunology |
| title | Mucosal delivery of RNA vaccines by Newcastle disease virus vectors |
| title_full | Mucosal delivery of RNA vaccines by Newcastle disease virus vectors |
| title_fullStr | Mucosal delivery of RNA vaccines by Newcastle disease virus vectors |
| title_full_unstemmed | Mucosal delivery of RNA vaccines by Newcastle disease virus vectors |
| title_short | Mucosal delivery of RNA vaccines by Newcastle disease virus vectors |
| title_sort | mucosal delivery of rna vaccines by newcastle disease virus vectors |
| url | http://www.sciencedirect.com/science/article/pii/S2590255522000221 |
| work_keys_str_mv | AT adolfogarciasastre mucosaldeliveryofrnavaccinesbynewcastlediseasevirusvectors |